Literature DB >> 33125834

Duration of antiretroviral therapy among people living with HIV and incidence of hypertension in Ghana.

Fred Stephen Sarfo1,2, Arti Singh1, Raelle Tagge3, Gideon Mensah2, Bruce Ovbiagele4.   

Abstract

Understanding the differential rates of incident hypertension among People Living with HIV (PLWH) based of duration of exposure to combination antiretroviral therapy (cART) may provide insights into the pathogenesis of hypertension in this population. Utilizing the dataset of a prospective study conducted at a Ghanaian tertiary medical center, we evaluated factors associated with incident hypertension among PLWH previously naïve to cART before study enrollment (cART newly prescribed group, n = 221) versus PLWH established on cART for at least a year (cART established group, n = 212). New-onset hypertension was diagnosed as clinic BP > 140/90 mmHg on two separate clinic visits over 12-month follow-up. Cox proportional hazards regression models were used to assess factors associated with incident hypertension. Mean age of new versus cART established was 41.1 ± 8.2 versus 45.1 ± 8.6 years (p < .001), with more women in the cART established group (68.3 vs. 82%, p = .0009). There were 105 (24.3%) episodes of incident hypertension over 328 person-years follow-up (PYFU), incidence rate of 320.1 (95% CI: 263.1-385.9)/1000 PYFU, with higher rates in new versus cART established (476.6/1000 PYFU vs. 222.8/1000 PYFU, p = 0.0002). Overall, age by increasing decile (aHR 0.76; 95% CI: 0.59-0.98), log HIV-1 viral load (aHR 1.16; 1.04-1.35), and use of tenofovir (aHR 1.66; 1.04-2.64) were associated with incident hypertension. While CD4 counts, age, BMI, pre-diabetes, and urban/peri-urban residency were independently associated with hypertension in the cART established group; no independent predictors were identified among the cART newly prescribed group. Further studies to explore the potential mechanisms underlying incidence of hypertension in PLWH are warranted.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  anti-retroviral therapy; hypertension; incidence; risk factors

Mesh:

Substances:

Year:  2020        PMID: 33125834      PMCID: PMC8030093          DOI: 10.1111/jch.14088

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  34 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

2.  Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003.

Authors:  Eric C Seaberg; Alvaro Muñoz; Ming Lu; Roger Detels; Joseph B Margolick; Sharon A Riddler; Carolyn M Williams; John P Phair
Journal:  AIDS       Date:  2005-06-10       Impact factor: 4.177

3.  Hypertension prevalence and Framingham risk score stratification in a large HIV-positive cohort in Uganda.

Authors:  Farrah J Mateen; Steve Kanters; Robert Kalyesubula; Barbara Mukasa; Esther Kawuma; Andre P Kengne; Edward J Mills
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

4.  Prehypertension, hypertension, and the risk of acute myocardial infarction in HIV-infected and -uninfected veterans.

Authors:  Kaku A Armah; Chung-Chou H Chang; Jason V Baker; Vasan S Ramachandran; Matthew J Budoff; Heidi M Crane; Cynthia L Gibert; Matthew B Goetz; David A Leaf; Kathleen A McGinnis; Krisann K Oursler; David Rimland; Maria C Rodriguez-Barradas; Jason J Sico; Alberta L Warner; Priscilla Y Hsue; Lewis H Kuller; Amy C Justice; Matthew S Freiberg
Journal:  Clin Infect Dis       Date:  2013-09-24       Impact factor: 9.079

5.  Renin modulates HIV replication in T cells.

Authors:  Nirupama Chandel; Kamesh Ayasolla; Xiqian Lan; Partab Rai; Joanna Mikulak; Mohammad Husain; Ashwani Malhotra; Joseph McGowan; Pravin C Singhal
Journal:  J Leukoc Biol       Date:  2014-06-26       Impact factor: 4.962

6.  Predictors of hypertension and changes of blood pressure in HIV-infected patients.

Authors:  Rodolphe Thiébaut; Wafaa M El-Sadr; Nina Friis-Møller; Martin Rickenbach; Peter Reiss; Antonella D'Arminio Monforte; Linda Morfeldt; Eric Fontas; Ole Kirk; Stephane De Wit; Gonzalo Calvo; Matthew G Law; François Dabis; Caroline A Sabin; Jens D Lundgren
Journal:  Antivir Ther       Date:  2005

7.  Prevalence of Hypertension in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) Compared with HAART-Naïve Patients at the Limbe Regional Hospital, Cameroon.

Authors:  Christian Akem Dimala; Julius Atashili; Josephine C Mbuagbaw; Akam Wilfred; Gottlieb L Monekosso
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

Review 8.  HIV infection as vascular risk: A systematic review of the literature and meta-analysis.

Authors:  Jose Gutierrez; Ana Letícia A Albuquerque; Louise Falzon
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

9.  Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana.

Authors:  Fred Stephen Sarfo; Adetayo Kasim; Richard Phillips; Anna Maria Geretti; David R Chadwick
Journal:  J Infect       Date:  2014-06-27       Impact factor: 6.072

10.  Hypertension, kidney disease, HIV and antiretroviral therapy among Tanzanian adults: a cross-sectional study.

Authors:  Robert N Peck; Rehema Shedafa; Samuel Kalluvya; Jennifer A Downs; Jim Todd; Manikkam Suthanthiran; Daniel W Fitzgerald; Johannes B Kataraihya
Journal:  BMC Med       Date:  2014-07-29       Impact factor: 8.775

View more
  3 in total

1.  Prevalence and correlates of hypertension in HIV-positive adults from the Livingstone Central Hospital, Zambia.

Authors:  Robert Musekwa; Benson Malambo Hamooya; John Robert Koethe; Selestine Nzala; Sepiso Kenias Masenga
Journal:  Pan Afr Med J       Date:  2021-08-12

Review 2.  HIV-1 Persistence in Children during Suppressive ART.

Authors:  Mary Grace Katusiime; Gert U Van Zyl; Mark F Cotton; Mary F Kearney
Journal:  Viruses       Date:  2021-06-12       Impact factor: 5.048

3.  Factors associated with incidence of stroke and heart failure among people living with HIV in Ghana: Evaluating Vascular Event Risk while on Long-Term Antiretroviral Suppressive Therapy (EVERLAST) Study.

Authors:  Fred Stephen Sarfo; Betty Norman; Lambert Appiah; Bruce Ovbiagele
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-05-03       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.